July 21, 2017 08:12 AM EDT

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

John Carroll

Editor & Founder

Nektar Therapeutics’ $NKTR attempt to win an accelerated European OK for its cancer drug Onzeald (NKTR-102) has run straight into a regulatory brick wall. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

We’re about to find out which RFK Jr. will show up at HHS

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Astellas shakes up management despite impressive nine-month earnings

Merck CEO says he’s confident in growth despite Gardasil ‘headwind’

Nek­tar’s pitch on ear­ly can­cer drug OK runs in­to a reg­u­la­to­ry brick wall

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall